TXG
10x GenomicsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Bull thesis: successful commercial translation of multi-omics and single-cell expansion leads to sustained top-line growth, operating leverage, and re-rating toward premium instrument/computational peers.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.4.
What can break
Execution risk scaling manufacturing and sales
Momentum
99
Value
50
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $18.54 · Bull $27.18 · Bear $12.68
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-02-14 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $39.85
Why
Momentum99 · Δ7d +0.4
Value50 · Δ7d +0.0
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
99
26% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+1.8
Value
50
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.3
Sentiment
0
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.3
Why this grade
Composite grade D. Momentum 98.8 / Value 49.7 / Sentiment 0.0
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$5.99B
Beta
2.23
Shares Out
126.96M
P/E (TTM) · Derived
-135.2
P/S (TTM)
3.61
P/FCF (TTM)
28.39
Rev YoY
-2.6%
EPS YoY
-62.5%
Gross Margin
+70.5%
Op Margin
-14.2%
Net Debt
-$439.05M
Current Ratio
5.90
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology